Search AVHHL
AVITA Medical, Inc.
Nasdaq, OTC · CIK 1762303
Last close1.96
Daily change+0.00 (0.00%)
10 Years gain+13.15%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AVHHL · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
39.5Momentum
100.0Acceleration
100.0Confidence
75.0Annual Revenue8
Quarterly Revenue33
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.4 / 25
Quality14.4 / 25
Capital Efficiency3.0 / 20
Balance Sheet1.1 / 15
Shareholder Economics1.6 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 24.4206 percentage points.
ROIC expansionROIC improved by 179.9106 percentage points.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 3.9335 percentage points.
Heavy share dilution · HIGHDiluted share count increased 17.1265%.
Low interest coverage · HIGHInterest coverage is -6.6505x.
Key Metrics
Revenue Growth TTM6.66%OK
Revenue CAGR 3Y27.66%OK
Gross Margin81.53%OK
Operating Margin-47.05%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-302.84%OK
Incremental Operating Margin 3Y-20.59%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y17.13%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $71.61M | $58.82M | -$42.53M | n/a | n/a | 82.13% | -59.4% | n/a | -155.2% | 27.86M |
| 2025 FY Dec 31, 2024 | $64.25M | $55.16M | -$56.59M | n/a | n/a | 85.85% | -88.08% | n/a | -361.72% | 25.88M |
| 2024 FY Dec 31, 2023 | $50.14M | $42.36M | -$42.66M | -$38.01M | -$39.39M | 84.48% | -85.07% | -78.56% | -1,293.82% | 25.33M |
| 2023 FY Dec 31, 2022 | $34.42M | $28.38M | -$27.51M | -$19.09M | -$19.54M | 82.45% | -79.91% | -56.77% | -421.63% | 25M |
| 2022 FY Jun 30, 2021 | $29.23M | $23.28M | -$26.54M | -$25.90M | -$26.80M | 79.65% | -90.79% | -91.66% | -1,142.28% | 22.67M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $76.43M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-338101, 0001193125-25-269597 |
| Revenue Growth TTM | 6.66% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-338101, 0001193125-25-269597 |
| Revenue CAGR 3Y | 27.66% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-049031 |
| Revenue CAGR 5Y | 38.09% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-049031 |
| Gross Profit CAGR 3Y | 27.5% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-049031 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-338101, 0001193125-25-269597 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 81.53% | Gross Profit / Revenue | OK | 0001193125-26-338101, 0001193125-25-269597 |
| Operating Margin | -47.05% | Operating Income / Revenue | OK | 0001193125-26-338101, 0001193125-25-269597 |
| ROIC | -302.84% | NOPAT / Average Invested Capital | OK | 0001193125-26-338101, 0001193125-25-269597 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-338101 |
| Interest Coverage | -6.65x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0.41x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.24x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-338101 |